Dr. David P. Galloway, M.D.
Pediatrics (Pediatrics Physician)
At a glance
- Medical school
- Texas A & M University System, Hsc, College of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2010
Licensed in Alabama since 2015, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Texas A & M University System, Hsc, College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
AL license 34305 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Nafcillin Sodium | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $93.72 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $48.85 |
|---|---|
| Alcresta Therapeutics, Inc. | $44.87 |
| Food and Beverage | $93.72 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,914 in research payments for these studies, mostly to the institutions running them.
- Registry for Participants With Short Bowel Syndrome
Takeda Pharmaceuticals U.S.A., Inc. · Active, not recruiting · NCT01990040
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.